Peptide Based Cancer Therapeutics Market Grow to Just Over US$ 11,160 Mn by 2022-end: According to Fact.MR

Fact.MR Fact.MR

Dublin 2, Ireland, 2018-Jun-04 — /EPR Network/ — Recently, a novel report developed using proven research methodologies at the headquarters of Fact. MR has identified various prominent factors and trends prompting market growth of peptide based cancer therapeutics market. The study is titled as Peptide Based Cancer Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Review 2017 to 2022”, which deeply analyses the global market trends, with historical data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) during the mentioned forecast of 2017-2022. For the benefit of the readers, the report concludes with a special focus on the detailed profiles of the major vendors in the global peptide based cancer therapeutics market.

Request for Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=179

Peptide is a compound that is created by artificial or natural biological chaining of amino acid monomers. In recent years, peptides have emerged as an effective therapeutic agent in treatment of various diseases, including cancer. At present, there are a number of peptide based cancer therapeutics available in the market.  Incessant medical research on peptides has led to development of several peptide based cancer therapeutics that are showing greater results as compared to conventional cancer therapeutics. Fact.MR’s latest report projects that the global peptide based cancer therapeutics market will surpass a valuation of US$ 11,160 Mn by 2022-end, expanding at an impressive CAGR of 9.2% during the forecast period (2017-2022).

Forecast Highlights Of Global Market For Peptide Based Cancer Therapeutics

1. Among regions, North America is expected to remain the most attractive market for peptide based cancer therapeutics during the forecast period. This is largely due to the existence of several prominent peptide based cancer therapeutic drug makers and an advanced healthcare infrastructure in the region. Over the next couple of years, the region’s market is projected to witness a healthy growth. Meanwhile, the market in Asia-Pacific excluding Japan (APEJ) is anticipated to register the fastest CAGR over 2022.

2. Based on drugs, demand for bortezomib is expected to remain relative higher as compared to other peptide based cancer therapeutic drugs.  Revenues from global sales of bortezomib drugs currently commands for nearly 40% market share.  Towards the end of 2022, more than US$ 4,700 Mn worth bortezomib drugs are estimated to be sold worldwide.

3. Hospital pharmacies are the largest distribution channel for peptide based cancer therapeutic drugs followed by retail pharmacies. Currently, hospital pharmacies account for close to 50% share of the global market in terms of revenue. The trend is likely to continue in 2017 and beyond.

Browse Full Report with TOC- https://www.factmr.com/report/179/peptide-based-cancer-therapeutics-market

North America To Lead The Global Peptide Based Cancer Therapeutics Market

In terms of revenues, North America is expected to dominate the global peptide based cancer therapeutics market in 2017 and beyond. The region’s potency in healthcare and a strong presence of various peptide based cancer therapeutic drug manufacturers is supporting the growth of the market in North America. During the forecast period, the market in the region is expected to surge at a robust CAGR.

On the basis of drugs, the bortezomib segment is expected to remain highly attractive throughout the assessment period. The segment currently accounts for around 40% revenue share of the global market. Between 2017 and 2022, the segment is expected to reflect a double-digit CAGR to reach a valuation is excess of US$ 4,725 Mn. It expected to grow at US$ 358.4 Mn annually over the course of the forecast period.

Competition Tracking

Fact.MR’s report has also profiled key companies that are operating in the global peptide based cancer Therapeutic market, which include AstraZeneca PLC, Allergan plc, Pfizer Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Abbott, AbbVie Inc., and Valeant Pharmaceuticals International, Inc.

Request Methodology of the Report- https://www.factmr.com/connectus/sample?flag=RM&rep_id=179

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized  Healthcare market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Fact.MR
Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Telephone: +353-1-6111-593
Email: sales@factmr.com
Web: https://www.factmr.com/
Follow us in Linkedin: https://www.linkedin.com/company/factmr/

Matched content

Editor’s pick

Express Press Release Distribution